Navigation Links
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
Date:5/31/2008

ancer before it reaches an advanced stage. A tumor passes through six stages on its path to metastasizing (spreading)(4). In the laboratory, Zometa has been shown to make passage through these stages more difficult by inhibiting angiogenesis (formation of blood vessels that grow and feed cancer cells), stimulating cancer-fighting T-cells, inducing tumor cell apoptosis (programmed cell death) and increasing the activity of anticancer agents that target tumor cell metastases(5).

A growing number of clinical studies are examining the potential anticancer impact of Zometa. One of the largest of these studies, AZURE (Adjuvant Zoledronic acid to redUce REcurrence), has completed enrollment. The study will evaluate the impact of Zometa in reducing risk of cancer recurrence in 3,360 premenopausal and postmenopausal women with Stage II/III breast cancer.

Another study presented at this year's ASCO meeting evaluated the effect of Zometa on bone marrow micrometastases. The study was conducted in 120 premenopausal and postmenopausal women with Stage II/III breast cancer undergoing treatment pre- and post-surgery. For those women who were negative for disseminated cancer cells at baseline, significantly more women who took Zometa in addition to chemotherapy remained negative for disseminated cancer cells over time.

Study Details

The Austrian Breast & Colorectal Cancer Study Group Trial 12 (ABCSG-12) is an open-label, multicenter, Phase III study that enrolled 1,803 premenopausal women with estrogen-receptor-positive Stage I or II breast cancer, with fewer than 10 axillary lymph nodes involved. Patients were recruited for the study after curative surgery and initiation of goserelin treatment for ovarian suppression, and randomly assigned into one of four study groups: (1) anastrozole plus Zometa; (2) anastrozole alone; (3) tamoxifen plus Zometa; (4) tamoxifen alone. The treatment period was three years and the median follow-up period was an additional
'/>"/>

SOURCE Novartis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
2. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
3. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
6. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Video: New Research Discovers Independent Brain Networks Control Human Walking
9. BioElectronics Announces Major Clinical Trials
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Ill. , July 1, 2015 ... nationwide group of state and regional professional rheumatology ... survey of rheumatologists that explored perceptions of biosimilars ... on patients. Biosimilars are medicines ... biologic medicines. They are notably different from generic ...
(Date:7/1/2015)... 1, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... corporate presentation at the Cantor Fitzgerald Healthcare Conference in ... Russell Cox , executive vice president and chief ... a business and financial update on Wednesday, July 8, 2015 ... A live audio webcast of the presentation may be ...
(Date:7/1/2015)... , July 1, 2015 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... Fitzgerald Inaugural Healthcare Conference taking place in ... at Le Parker Meridien Hotel. ... overview of the Company,s business during his live presentation ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... 3 Glufosfamide and Phase 2 Glufosfamide Plus ... Gemcitabine Clinical Trials to be Presented, REDWOOD CITY, Calif., ... announced two presentations,regarding its oncology product candidate glufosfamide. The presentations,will ... held,September 23 to 27, 2007, at the International Conference Center ...
... First Hsp90 Inhibitor to Enter Registration Trials, HAYWARD, ... ) today announced that it has successfully,reached a binding ... the design of its TIME-1 clinical trial, a pivotal ... treatment for patients with,multiple myeloma. Through the FDA,s Special ...
Cached Medicine Technology:Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 2Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:7/1/2015)... ... July 01, 2015 , ... SuiteRx, innovative leaders in pharmacy ... pharmacy operations, announces the most recent positioning of SuiteRx CEO, Nicholas Zener Pharm. ... at the Venetian Las Vegas, Nevada. During this event, SuiteRx will be ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The Collaborative ... the New York Community Trust. The grant will allow CCF to improve quality of ... practices. , CCF was formed to respond to many changes in New York’s Medicaid ...
(Date:7/1/2015)... ... , ... Did you know that infertility in men is more common than ... Fertility Center of Texas (AFCT) would like to talk about some natural ways to ... to be a “woman’s issue,” male fertility factors can play a role in about ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... said lead author Lisa Stolzenberg, a Professor in FIU’s School of International and ... 12 to 17 years who participated in the National Survey on Drug Use ...
(Date:7/1/2015)... ... 2015 , ... Franklin University, one of the leading educators of working adults ... named Dean of the College of Health & Public Administration . ... vision and mission of Franklin University via curriculum planning, course scheduling, faculty staffing and ...
Breaking Medicine News(10 mins):Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 2Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 4Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Franklin University Appoints Dean of College of Health & Public Administration 2
... NOAA-supported scientists from the Louisiana Universities Marine Consortium and Louisiana ... coast of Louisiana and Texas in the Gulf of Mexico ... researchers are predicting the area could measure a record 8,800 ... 2007, the dead zone was 7,903 square miles. The largest ...
... of Industry ... Standards, ... exchange, today announced it has received full,accreditation by The Electronic Healthcare ... peer,evaluation of an organization,s ability to perform at industry established,levels., ...
... Company (NYSE: PG ) confirmed previously announced sales and ... 2007/08. The company,continues to expect sales growth for the quarter ... with previous guidance and diluted,earnings per share of $0.76 to ... available. P&G is scheduled,to announce the final results for the ...
... PRUSSIA, Pa., July 15 HighPoint Solutions LLC,a ... that it,has been selected by one of the ... a Contract Analytics Reporting & Scorecard solution. This,project ... reports, scorecards and dashboards, resulting in a complete ...
... shown an association between certain past diagnostic radiation procedures ... a rare form of prostate cancer which affects about ... disease. , The study, the first of its kind ... from diagnostic procedures and the risk of prostate cancer, ...
... the University of Warwick have discovered diabetes could be a ... In a study led by Dr Saverio Stranges, Associate Professor ... at levels of oxidative stress in the body (a toxic ... levels of oxidative stress in people with coronary heart disease, ...
Cached Medicine News:Health News:NOAA and Louisiana scientists predict largest Gulf of Mexico 'dead zone' on record 2Health News:Availity Awarded Full EHNAC Accreditation 2Health News:Availity Awarded Full EHNAC Accreditation 3Health News:Procter & Gamble Confirms Prior Sales and Earnings Guidance for Fourth Quarter 2007/08 2Health News:Procter & Gamble Confirms Prior Sales and Earnings Guidance for Fourth Quarter 2007/08 3Health News:HighPoint Solutions to Develop Contract Analytics Solution for a Top Three Pharmaceutical Company 2Health News:Possible link found between X-rays and prostate cancer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: